Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains

References

• WHO. Global tuberculosis report 2020. World Health Organization, 2020.
   Google Scholar
• Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol. 2009;157(2):235–7. doi:10.1111/j.1365-2249.2009.03967.x.
   PubMed Web of Science ®Google Scholar
• Antas PR, Castello-Branco LR. New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil. Trans R Soc Trop Med Hyg. 2008;102(7):628–30. doi:10.1016/j.trstmh.2008.03.014.
   PubMed Web of Science ®Google Scholar
• Zodpey SP. The BCG controversy: a reappraisal of the protective effect against tuberculosis and leprosy. Indian J Public Health. 2004;48:70–77.
   PubMedGoogle Scholar
• Pereira SM, Dantas OM, Ximenes R, Barreto ML. [BCG vaccine against tuberculosis: its protective effect and vaccination policies]. Rev Saude Publica. 2007;41(Suppl 1):59–66. doi:10.1590/S0034-89102007000800009.
   PubMedGoogle Scholar
• Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271:698–702. doi:10.1001/jama.1994.03510330076038
   Google Scholar
• Pe F. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346(8986):1339–45. doi:10.1016/S0140-6736(95)92348-9.
   PubMed Web of Science ®Google Scholar
• Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, Andersen P. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental Mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun. 2002;70(2):672–78. doi:10.1128/IAI.70.2.672-678.2002.
   PubMed Web of Science ®Google Scholar
• Triccas JA. Recombinant BCG as a vaccine vehicle to protect against tuberculosis. Bioeng Bugs. 2010;1(2):110–15. doi:10.4161/bbug.1.2.10483.
   PubMedGoogle Scholar
• Stanford JL. Improving on BCG. APMIS. 1991;99(1–6):103–13. doi:10.1111/j.1699-0463.1991.tb05127.x.
   PubMedGoogle Scholar
• Grover A, Taylor J, Troudt J, Keyser A, Arnett K, Izzo L, Rholl D, Izzo A. Kinetics of the immune response profile in Guinea pigs after vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis. Infect Immun. 2009;77(11):4837–46. doi:10.1128/IAI.00704-09.
   PubMed Web of Science ®Google Scholar
• Antas PR. Crucial requirement for standardization during the development of novel recombinant BCG vaccines: does the corresponding substrain background matter? Hum Vaccin Immunother. 2016;12(12):3099–102. doi:10.1080/21645515.2016.1212145.
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, Dos Santos S, Duthoy S, Lacroix C, Garcia-Pelayo C. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007;104(13):5596–601. doi:10.1073/pnas.0700869104.
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine. 2009;27(3):441–45. doi:10.1016/j.vaccine.2008.10.058.
   PubMed Web of Science ®Google Scholar
• Dagg B, Hockley J, Rigsby P, Ho MM. The establishment of sub-strain specific WHO reference reagents for BCG vaccine. Vaccine. 2014;32(48):6390–95. doi:10.1016/j.vaccine.2014.09.065.
   PubMed Web of Science ®Google Scholar
• Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD, Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun. 1996;64(1):1–9. doi:10.1128/iai.64.1.1-9.1996.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Webb EL, Mawa PA, Kizza M, Lyadda N, Nampijja M, Elliott AM. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine. 2012;30(12):2083–89. doi:10.1016/j.vaccine.2012.01.053.
   PubMed Web of Science ®Google Scholar
• Hayashi D, Takii T, Fujiwara N, Fujita Y, Yano I, Yamamoto S, Kondo M, Yasuda E, Inagaki E, Kanai K. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guérin (BCG) substrains. FEMS Immunol Med Microbiol. 2009;56(2):116–28. doi:10.1111/j.1574-695X.2009.00559.x.
   PubMed Web of Science ®Google Scholar
• Wang JF, Dai FY, Gong XL, Bao L. Commonly administered bacille Calmette-Guerin strains induce comparable immune response. Int J Clin Exp Med. 2015;8:15834–39.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, Fine P, Smith PG, Lipman M, Elliman D, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):v–vi. doi:10.3310/hta17370.
   Web of Science ®Google Scholar
• Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–80. doi:10.1093/cid/cit790.
   PubMed Web of Science ®Google Scholar
• Shann F. Editorial commentary: different strains of Bacillus Calmette-Guerin vaccine have very different effects on tuberculosis and on unrelated infections. Clin Infect Dis. 2015;61:960–62. doi:10.1093/cid/civ454.
   PubMed Web of Science ®Google Scholar
• Antas PRZ, Flores-Valdez M, Shann F. An opportunity to compare the effects of BCG-Moreau and BCG-Russia in Brazil. Int J Tuberc Lung Dis. 2018;22(9):1108–09. doi:10.5588/ijtld.18.0271.
   PubMed Web of Science ®Google Scholar
• Ponte C, Hacker M, Moraes M, Castello-Branco L, Silva F, Antas P. The patterns of in vitro cell-death and inflammatory cytokines induced by distinct BCG vaccine strains are differentially induced in human mononuclear cells. Hum Vaccin Immunother. 2018;14(1):28–35. doi:10.1080/21645515.2017.1382788.
   PubMed Web of Science ®Google Scholar
• Mawa PA, Webb EL, Filali-Mouhim A, Nkurunungi G, Sekaly RP, Lule SA, Prentice S, Nash S, Dockrell HM, Elliott AM, et al. Maternal BCG scar is associated with increased infant proinflammatory immune responses. Vaccine. 2017;35(2):273–82. doi:10.1016/j.vaccine.2016.11.079.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhang X, Liu J, Liu Y, Zhao C, Cai H, Lei W, Ma J, Fan H, Zhou J, et al. The correlations between Th1 and Th2 cytokines in human alveolar echinococcosis. BMC Infect Dis. 2020;20(1):414. doi:10.1186/s12879-020-05135-y.
   PubMed Web of Science ®Google Scholar
• Pawaria S, Lama A, Raje M, Dikshit KL. Responses of Mycobacterium tuberculosis hemoglobin promoters to in vitro and in vivo growth conditions. Appl Environ Microbiol. 2008;74(11):3512–22. doi:10.1128/AEM.02663-07.
   PubMed Web of Science ®Google Scholar
• Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol. 2003;57(1):641–76. doi:10.1146/annurev.micro.57.030502.091033.
   PubMedGoogle Scholar
• World Health Organization. BCG vaccine: WHO position paper, February 2018 - Recommendations. Vaccine 2018.
   Google Scholar
• Sanarico N, Colone A, Grassi M, Speranza V, Giovannini D, Ciaramella A, Colizzi V, Mariani F. Different transcriptional profiles of human monocyte-derived dendritic cells infected with distinct strains of Mycobacterium tuberculosis and Mycobacterium bovis bacillus Calmette-Guérin.Clin Dev Immunol. 2011;2011:741051. doi:10.1155/2011/741051
   Google Scholar
• Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants–mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol. 2008;76:353–59.
   PubMedGoogle Scholar
• Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204–18. doi:10.18632/oncotarget.23208.
   PubMedGoogle Scholar
• Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, Robins-Browne R, Hanekom WA, Britton WJ, Curtis N. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med. 2012;185(2):213–22. doi:10.1164/rccm.201104-0714OC.
   PubMed Web of Science ®Google Scholar
• Kiravu A, Osawe S, Happel AU, Nundalall T, Wendoh J, Beer S, Dontsa N, Alinde OB, Mohammed S, Datong P, et al. Bacille Calmette-Guérin vaccine strain modulates the ontogeny of both Mycobacterial-specific and heterologous T cell immunity to vaccination in infants. Front Immunol. 2019;10:2307. doi:10.3389/fimmu.2019.02307.
   PubMed Web of Science ®Google Scholar
• Masters SL, Mielke LA, Cornish AL, Sutton CE, O’Donnell J, Cengia LH, et al. Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep. 2010;11(8):640–46. doi:10.1038/embor.2010.93.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8–27.
   PubMed Web of Science ®Google Scholar
• Pollara G, Turner CT, Rosenheim J, Chandran A, Bell LCK, Khan A, et al. Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. Sci Transl Med. 2021;13.
   Web of Science ®Google Scholar
• Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009;30(4):576–87. doi:10.1016/j.immuni.2009.02.007.
   PubMed Web of Science ®Google Scholar
• Fatima S, Kumari A, Das G, Dwivedi VP. Tuberculosis vaccine: a journey from BCG to present. Life Sci. 2020;252:117594. doi:10.1016/j.lfs.2020.117594.
   PubMed Web of Science ®Google Scholar
• Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis. 1994;75(3):179–80. doi:10.1016/0962-8479(94)90003-5.
   PubMedGoogle Scholar
• Dierig A, Tebruegge M, Krivec U, Heininger U, Ritz N; (ptbnet) PTNETg. Current status of Bacille Calmette Guérin (BCG) immunisation in Europe – a ptbnet survey and review of current guidelines. Vaccine. 2015;33(38):4994–99. doi:10.1016/j.vaccine.2015.06.097.
   PubMed Web of Science ®Google Scholar
• Tu HA, Vu HD, Rozenbaum MH, Woerdenbag HJ, Postma MJ. A review of the literature on the economics of vaccination against TB. Expert Rev Vaccines. 2012;11(3):303–17. doi:10.1586/erv.11.197.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Tala-Heikkilä M, Tala E, Tosteson AN, Fordham von Reyn C. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland. Int J Tuberc Lung Dis. 2003;7:22–29.
   PubMed Web of Science ®Google Scholar
• Feiring B, Laake I, Molden T, Håberg SE, Nøkleby H, Seterelv SS, Magnus P, Trogstad L. Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme. Vaccine. 2016;34(17):2015–20. doi:10.1016/j.vaccine.2016.02.060.
   PubMed Web of Science ®Google Scholar
• Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, Diness BR, Lausch KR, Lund N. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204(2):245–52. doi:10.1093/infdis/jir240.
   PubMed Web of Science ®Google Scholar
• Stensballe LG, Ravn H, Birk NM, Kjærgaard J, Nissen TN, Pihl GT, et al. BCG vaccination at birth and rate of hospitalization for infection until 15 months of age in Danish children: a randomized clinical multicenter trial. J Pediatric Infect Dis Soc. 2018.
   Web of Science ®Google Scholar
• Biering-Sørensen S, Aaby P, Lund N, Monteiro I, Jensen KJ, Eriksen HB, et al. Early BCG-Denmark and Neonatal mortality among infants weighing <2500 g: a randomized controlled trial. Clin Infect Dis. 2017;65:1183–90.
   PubMed Web of Science ®Google Scholar
• Brook B, Harbeson DJ, Shannon CP, Cai B, He D, Ben-Othman R, et al. BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis. Sci Transl Med. 2020;12.
   Web of Science ®Google Scholar
• O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020;20(6):335–37. doi:10.1038/s41577-020-0337-y.
   PubMed Web of Science ®Google Scholar
• Gomez M, Doukhan L, Nair G, Smith I. sigA is an essential gene in Mycobacterium smegmatis. Mol Microbiol. 1998;29(2):617–28. doi:10.1046/j.1365-2958.1998.00960.x.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol. 2012;23(6):900–07. doi:10.1016/j.copbio.2012.03.007.
   PubMed Web of Science ®Google Scholar
• Collins DM. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex. Immunol Cell Biol. 2000;78(4):342–48. doi:10.1046/j.1440-1711.2000.00937.x.
   PubMed Web of Science ®Google Scholar
• Hanson MS, Lapcevich CV, Haun SL. Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery. Ann N Y Acad Sci. 1995;754:214–21. doi:10.1111/j.1749-6632.1995.tb44453.x.
   PubMed Web of Science ®Google Scholar
• Ohara N, Yamada T. Recombinant BCG vaccines. Vaccine. 2001;19(30):4089–98. doi:10.1016/S0264-410X(01)00155-4.
   PubMed Web of Science ®Google Scholar
• Wada T, Maruyama F, Iwamoto T, Maeda S, Yamamoto T, Nakagawa I, Yamamoto S, Ohara N. Deep sequencing analysis of the heterogeneity of seed and commercial lots of the bacillus Calmette-Guérin (BCG) tuberculosis vaccine substrain Tokyo-172. Sci Rep. 2015;5(1):17827. doi:10.1038/srep17827.
   PubMedGoogle Scholar
• Hanekom WA. The immune response to BCG vaccination of newborns. Ann N Y Acad Sci. 2005;1062(1):69–78. doi:10.1196/annals.1358.010.
   PubMedGoogle Scholar